| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$192,145 ) |
| | 2025 | 2022 | INTERVEXION THERAPEUTICS LLC | 4301 W MARKHAM ST # 831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA053043 | Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS | 000 | 3 | NIH | 11/13/2024 | -$192,145 |
|
| Issue Date FY: 2024 ( Subtotal = $3,970,218 ) |
| | 2024 | 2024 | INTERVEXION THERAPEUTICS LLC | 4301 W MARKHAM ST # 831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA056240 | IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder | 000 | 3 | NIH | 7/23/2024 | $4,314,989 |
| | 2024 | 2022 | INTERVEXION THERAPEUTICS LLC | 4301 W MARKHAM ST # 831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA051078 | Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization | 000 | 3 | NIH | 7/8/2024 | -$344,771 |
|
| Issue Date FY: 2023 ( Subtotal = $8,790,532 ) |
| | 2023 | 2023 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA056240 | IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder | 002 | 2 | NIH | 7/19/2023 | $4,336,347 |
| | 2023 | 2023 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA055481 | OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder | 001 | 3 | NIH | 8/17/2023 | $4,609,902 |
| | 2023 | 2022 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA051078 | Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization | 000 | 3 | NIH | 2/9/2023 | $0 |
| | 2023 | 2022 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA056240 | IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder | 000 | 1 | NIH | 11/23/2022 | $0 |
| | 2023 | 2022 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA056240 | IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder | 001 | 1 | NIH | 12/1/2022 | $0 |
| | 2023 | 2022 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA053043 | Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS | 000 | 3 | NIH | 1/20/2023 | $0 |
| | 2023 | 2022 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA053043 | Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS | 001 | 3 | NIH | 4/11/2023 | $0 |
| | 2023 | 2022 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA051078 | Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization | 001 | 3 | NIH | 6/30/2023 | $0 |
| | 2023 | 2022 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA055481 | OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder | 000 | 2 | NIH | 2/10/2023 | $0 |
| | 2023 | 2019 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA045366 | STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy | 000 | 3 | NIH | 8/28/2023 | -$155,717 |
|
| Issue Date FY: 2022 ( Subtotal = $9,798,594 ) |
| | 2022 | 2022 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA053043 | Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS | 000 | 3 | NIH | 6/29/2022 | $1,863,102 |
| | 2022 | 2022 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA051078 | Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization | 001 | 3 | NIH | 3/30/2022 | $211,598 |
| | 2022 | 2022 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA055481 | OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder | 001 | 2 | NIH | 8/18/2022 | $4,570,609 |
| | 2022 | 2022 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA056240 | IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder | 000 | 1 | NIH | 9/19/2022 | $1,248,915 |
| | 2022 | 2022 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA051078 | Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization | 000 | 3 | NIH | 2/25/2022 | $1,904,370 |
| | 2022 | 2021 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA055481 | OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder | 000 | 1 | NIH | 10/8/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $11,513,394 ) |
| | 2021 | 2021 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA051078 | Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization | 000 | 2 | NIH | 3/1/2021 | $3,165,675 |
| | 2021 | 2021 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA055481 | OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder | 000 | 1 | NIH | 9/22/2021 | $4,597,509 |
| | 2021 | 2021 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA055481 | OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder | 001 | 1 | NIH | 9/27/2021 | $0 |
| | 2021 | 2021 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA053043 | Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS | 002 | 2 | NIH | 6/9/2021 | $3,750,210 |
| | 2021 | 2020 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA053043 | Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS | 001 | 1 | NIH | 4/20/2021 | $0 |
| | 2021 | 2020 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA053043 | Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS | 000 | 1 | NIH | 11/13/2020 | $0 |
| | 2021 | 2019 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA045366 | STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy | 000 | 3 | NIH | 7/13/2021 | $0 |
| | 2021 | 2019 | INTERVEXION THERAPEUTICS, LLC. | 401 S CEDAR ST | LITTLE ROCK | AR | 72205-5514 | PULASKI | USA | U01DA045366 | STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy | 001 | 3 | NIH | 9/29/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $5,633,272 ) |
| | 2020 | 2020 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA053043 | Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS | 000 | 1 | NIH | 9/25/2020 | $2,492,018 |
| | 2020 | 2020 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA051078 | Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization | 000 | 1 | NIH | 4/29/2020 | $3,136,427 |
| | 2020 | 2019 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA045366 | STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy | 000 | 3 | NIH | 10/29/2019 | $0 |
| | 2020 | 2019 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA045366 | STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy | 001 | 3 | NIH | 2/20/2020 | $0 |
| | 2020 | 2016 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA035511 | A Methamphetamine Conjugate Vaccine: From Manufacturing to IND | 000 | 3 | NIH | 5/20/2020 | $4,827 |
|
| Issue Date FY: 2019 ( Subtotal = $1,668,672 ) |
| | 2019 | 2019 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA045366 | STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy | 002 | 3 | NIH | 9/17/2019 | $0 |
| | 2019 | 2019 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA045366 | STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy | 001 | 3 | NIH | 9/6/2019 | $1,429,307 |
| | 2019 | 2019 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA045366 | STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy | 000 | 3 | NIH | 7/23/2019 | $938,893 |
| | 2019 | 2017 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA037593 | Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb | 000 | 3 | NIH | 10/27/2018 | -$50,478 |
| | 2019 | 2016 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA035511 | A Methamphetamine Conjugate Vaccine: From Manufacturing to IND | 000 | 3 | NIH | 9/27/2019 | -$649,050 |
|
| Issue Date FY: 2018 ( Subtotal = $2,735,856 ) |
| | 2018 | 2018 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA045366 | STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy | 000 | 2 | NIH | 8/10/2018 | $2,735,856 |
| | 2018 | 2016 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA035511 | A Methamphetamine Conjugate Vaccine: From Manufacturing to IND | 000 | 3 | NIH | 5/3/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $4,796,717 ) (Continued on the next page) |
| | 2017 | 2017 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA045366 | STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy | 001 | 1 | NIH | 9/28/2017 | $108,027 |
| | 2017 | 2017 | INTERVEXION THERAPEUTICS, LLC. | 4301 W MARKHAM #831 | LITTLE ROCK | AR | 72205-7101 | PULASKI | USA | U01DA045366 | STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy | 000 | 1 | NIH | 9/26/2017 | $4,493,715 |
|
